Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 627 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Design Therapeutics, Inc.
Market Cap
$755.11M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$760.77M
Gross Margin
40.44%
TTM Avg
20.22%
3Y Avg
20.22%
5Y Avg
20.22%
Market Cap
$753.58M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$768.31M
Gross Margin
65.99%
TTM Avg
63.07%
3Y Avg
62.20%
5Y Avg
62.16%
Market Cap
$769.83M
Gross Margin
97.42%
TTM Avg
97.90%
3Y Avg
98.95%
5Y Avg
-3197.94%
Market Cap
$770.68M
Gross Margin
98.85%
TTM Avg
98.73%
3Y Avg
-10570.46%
5Y Avg
-10093.61%
Market Cap
$716.10M
Gross Margin
53.23%
TTM Avg
53.64%
3Y Avg
56.38%
5Y Avg
57.18%
Market Cap
$718.57M
Gross Margin
100.00%
TTM Avg
141.50%
3Y Avg
99.31%
5Y Avg
94.19%
Market Cap
$726.83M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $755.11M | 0.00% | 0.00% | 0.00% | 0.00% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $760.77M | 40.44% | 20.22% | 20.22% | 20.22% |
| Candel Therapeutics, Inc. (CADL)vs › | $753.58M | 0.00% | 0.00% | 25.00% | 50.00% |
| Mesa Laboratories, Inc. (MLAB)vs › | $768.31M | 65.99% | 63.07% | 62.20% | 62.16% |
| Geron Corporation (GERN)vs › | $769.83M | 97.42% | 97.90% | 98.95% | -3197.94% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.68M | 98.85% | 98.73% | -10570.46% | -10093.61% |
| Cytek Biosciences, Inc. (CTKB)vs › | $716.10M | 53.23% | 53.64% | 56.38% | 57.18% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $718.57M | 100.00% | 141.50% | 99.31% | 94.19% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $726.83M | 0.00% | 0.00% | 0.00% | 0.00% |
| AdaptHealth Corp. (AHCO)vs › | $785.71M | 10.37% | 19.20% | 18.44% | 17.81% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
